Scientific article

Use of pneumococcal polysaccharide vaccine in children: what is the evidence?

Published inCurrent opinion in infectious diseases, vol. 25, no. 3, p. 292-303
Publication date2012

Pneumococcal glycoconjugate vaccines (PCVs) are now widely used in infant immunization schedules. These vaccines are also recommended for those at increased risk of pneumococcal infection and to provide optimal serotype coverage to those at increased risk of disease. The 23-valent polysaccharide vaccine (PPV23) is often advised from the second birthday to provide broader serotype coverage. The use of pneumococcal polysaccharide vaccines (PPVs) has in recent years become a topic of much debate, especially for use in children.

  • Adolescent
  • Child
  • Child, Preschool
  • Glycoconjugates/immunology
  • Humans
  • Immunization, Secondary/adverse effects
  • Immunocompromised Host
  • Infant
  • Pneumococcal Infections/prevention & control
  • Pneumococcal Vaccines/administration & dosage/adverse effects/immunology
  • Recurrence
  • Risk Factors
  • Vaccines, Conjugate/immunology
Citation (ISO format)
BORROW, Ray, HEATH, Paul T, SIEGRIST, Claire-Anne. Use of pneumococcal polysaccharide vaccine in children: what is the evidence? In: Current opinion in infectious diseases, 2012, vol. 25, n° 3, p. 292–303. doi: 10.1097/QCO.0b013e3283531b0f
Main files (1)
Article (Published version)
ISSN of the journal0951-7375

Technical informations

Creation10/08/2013 4:02:00 PM
First validation10/08/2013 4:02:00 PM
Update time03/14/2023 8:38:31 PM
Status update03/14/2023 8:38:30 PM
Last indexation01/16/2024 8:15:24 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack